iifl-logo

Sun Pharmaceuticals Industries Ltd Shareholding Pattern

1,832.3
(1.48%)
Apr 30, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharmaceuticals Industries Ltd SHAREHOLDING

Mar-2025Dec-2024Sep-2024Jun-2024Mar-2024

Promoter

-

-

-

-

-

Foreign

0%

0%

0%

0%

0%

Indian

54.47%

54.47%

54.47%

54.47%

54.47%

Total Promoter

-

-

-

-

-

Institutions

36.65%

36.59%

36.62%

36.5%

36.54%

Non-Institutions

8.86%

8.92%

8.89%

9.01%

8.97%

Total Non-Promoter

45.52%

45.52%

45.52%

45.52%

45.52%

Custodian

0%

0%

0%

0%

0%

Total

100%

100%

100%

100%

100%

  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 54.47%

Non-Promoter- 36.65%

Institutions: 36.65%

Non-Institutions: 8.86%

Custodian: 0.00%

Sun Pharma.Inds.: Related NEWS

Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis
26 Apr 2025|01:15 PM

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.